CN87102167A - 具交叉保护作用的人单克隆抗体组合物 - Google Patents

具交叉保护作用的人单克隆抗体组合物 Download PDF

Info

Publication number
CN87102167A
CN87102167A CN198787102167A CN87102167A CN87102167A CN 87102167 A CN87102167 A CN 87102167A CN 198787102167 A CN198787102167 A CN 198787102167A CN 87102167 A CN87102167 A CN 87102167A CN 87102167 A CN87102167 A CN 87102167A
Authority
CN
China
Prior art keywords
antibody
monoclonal antibody
serotype
escherichia coli
serratia marcescens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN198787102167A
Other languages
English (en)
Chinese (zh)
Inventor
霍华德·V·拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Systems Corp
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of CN87102167A publication Critical patent/CN87102167A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN198787102167A 1986-02-07 1987-02-06 具交叉保护作用的人单克隆抗体组合物 Pending CN87102167A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19
US944495 1992-09-14
US828005 1997-03-27

Publications (1)

Publication Number Publication Date
CN87102167A true CN87102167A (zh) 1988-02-03

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN198787102167A Pending CN87102167A (zh) 1986-02-07 1987-02-06 具交叉保护作用的人单克隆抗体组合物

Country Status (28)

Country Link
US (2) US5717071A (enExample)
JP (1) JP2645343B2 (enExample)
KR (1) KR870007697A (enExample)
CN (1) CN87102167A (enExample)
AT (1) AT398781B (enExample)
BE (1) BE1000967A5 (enExample)
CA (1) CA1339013C (enExample)
CH (1) CH672072A5 (enExample)
DE (1) DE3703711A1 (enExample)
DK (1) DK63187A (enExample)
ES (1) ES2009140A6 (enExample)
FI (1) FI94489C (enExample)
FR (1) FR2595946B1 (enExample)
GB (1) GB2186592B (enExample)
GR (1) GR870194B (enExample)
HK (1) HK21795A (enExample)
HU (1) HU203583B (enExample)
IE (1) IE59627B1 (enExample)
IL (1) IL81370A (enExample)
IT (1) IT1207589B (enExample)
LU (1) LU86761A1 (enExample)
MX (1) MX9203629A (enExample)
NL (1) NL8700286A (enExample)
NO (1) NO176924C (enExample)
NZ (2) NZ233920A (enExample)
OA (1) OA08477A (enExample)
PT (1) PT84258B (enExample)
SE (1) SE468747B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102378766A (zh) * 2009-03-23 2012-03-14 夸克医药公司 治疗癌症和纤维化疾病的化合物组合物和方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
WO1993019373A1 (en) * 1992-03-19 1993-09-30 U.S. GOVERNMENT, as represented by THE SECRETARY O Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
DE69942607D1 (de) * 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US8337846B2 (en) * 2007-07-23 2012-12-25 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
EP3374391B1 (en) * 2015-11-10 2024-04-17 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
US11969476B2 (en) 2020-04-03 2024-04-30 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
AU567693B2 (en) * 1982-09-30 1987-12-03 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102378766A (zh) * 2009-03-23 2012-03-14 夸克医药公司 治疗癌症和纤维化疾病的化合物组合物和方法

Also Published As

Publication number Publication date
FI94489C (fi) 1995-09-25
NO870476L (no) 1987-08-10
BE1000967A5 (fr) 1989-05-30
IT8719292A0 (it) 1987-02-06
HUT46062A (en) 1988-09-28
NZ233920A (en) 1990-12-21
AT398781B (de) 1995-01-25
DE3703711A1 (de) 1987-09-24
GB2186592B (en) 1990-08-01
FI94489B (fi) 1995-06-15
IL81370A (en) 1991-06-30
SE468747B (sv) 1993-03-15
HU203583B (en) 1991-08-28
FR2595946A1 (fr) 1987-09-25
DK63187A (da) 1987-08-08
CH672072A5 (enExample) 1989-10-31
GB2186592A (en) 1987-08-19
IE59627B1 (en) 1994-03-09
HK21795A (en) 1995-02-24
NO176924B (no) 1995-03-13
NL8700286A (nl) 1987-09-01
MX9203629A (es) 1992-07-01
GB8702689D0 (en) 1987-03-11
IT1207589B (it) 1989-05-25
US5717071A (en) 1998-02-10
JPS62270535A (ja) 1987-11-24
US5837541A (en) 1998-11-17
FR2595946B1 (fr) 1991-10-04
DE3703711C2 (enExample) 1993-06-24
GR870194B (en) 1987-06-10
DK63187D0 (da) 1987-02-06
JP2645343B2 (ja) 1997-08-25
NO176924C (no) 1995-06-21
FI870502A0 (fi) 1987-02-06
SE8700467D0 (sv) 1987-02-06
KR870007697A (ko) 1987-09-21
OA08477A (fr) 1988-07-29
ES2009140A6 (es) 1989-09-01
IE870320L (en) 1987-08-07
FI870502L (fi) 1987-08-08
LU86761A1 (fr) 1987-09-15
PT84258A (en) 1987-03-01
SE8700467L (sv) 1987-08-08
PT84258B (pt) 1989-09-14
ATA26287A (de) 1994-06-15
IL81370A0 (en) 1987-08-31
CA1339013C (en) 1997-03-25
NO870476D0 (no) 1987-02-06
NZ219187A (en) 1990-12-21

Similar Documents

Publication Publication Date Title
CN87102167A (zh) 具交叉保护作用的人单克隆抗体组合物
CN100351260C (zh) 葡萄球菌感染的多糖疫苗
CN1192241A (zh) Hsp70家族的链球菌热休克蛋白
CN1267553C (zh) 嗜血杆菌属转铁蛋白受体基因
CN1489474A (zh) 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
CN1142855A (zh) 人源化抗体及其用途
CN1505678A (zh) 作为治疗和预防变态反应的药物的乳酸菌
CN1118299C (zh) 淋球菌抗个体基因型抗体及其使用方法和组合物
CN1377410A (zh) 来自b族链球菌的核酸和蛋白质
CN1788018A (zh) 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体
TW565567B (en) Antigenic protein originating in Malassezia
Bidmos et al. Cross-reactive bactericidal antimeningococcal antibodies can be isolated from convalescing invasive meningococcal disease patients using reverse vaccinology 2.0
CN101062949A (zh) 重组抗人IgE单克隆抗体及其制备方法和用途
Fihiruddin et al. Expression and epitope prediction of MPT64 recombinant proteins from clinical isolates of Mycobacterium tuberculosis as immunoserodiagnostic candidates
CN1019133B (zh) 抗铜绿假单胞菌鞭毛的单克隆抗体
CN1737011A (zh) 抗hla－dr10的淋巴瘤特异性嵌合单抗
CN1219881A (zh) 山羊关节炎－脑炎病毒提供抗hiv－1感染的免疫保护
CN1253589A (zh) 来自肺炎链球菌的降解人类补体c3的蛋白酶
Kolberg et al. Streptococcus pneumoniae heat shock protein 70 does not induce human antibody responses during infection
CN1847397A (zh) 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
Burova et al. Autoimmune streptococcal glomerulonephritis: The problem of nephritogenicity of Streptococcus pyogenes
CN1683395A (zh) 核因子－κB p65亚基拮抗肽及其应用
CN1200002C (zh) 人黑色素瘤单克隆抗体，其制备方法及其应用
CN1670197A (zh) 日本血吸虫精氨酸酶，其编码核酸及其应用
CN1305898C (zh) 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication